APCCC 2024: In Which Patients with Metachronous Low-volume mHSPC Do You Recommend “total Therapy”?
APCCC 2024 metastatic hormone-sensitive prostate cancer (mHSPC), metachronous low-volume mHSPC, ‘total therapy’ with metastasis-directed therapy (MDT), ‘Pokemet’ approach,